Category: Biotech

May 5, 2022

Plunging valuations may be forcing biotechs to lay off staff and strip back their pipelines, but Big Pharma doesn’t think the price tags on offer are sufficiently tempting to justify a shopping trip quite yet. Judging by first-quarter earnings calls […]

May 5, 2022

The approval of Enhertu as a second-line option further establishes the drug’s growing role in breast cancer, where it’s quickly becoming a go-to treatment for the roughly 15% of patients with HER2-positive disease. First conditionally approved for third-line use in […]

May 4, 2022

Swiss biotechs saw record-breaking revenue and R&D investment in 2021, which the industry hopes will lead people to look beyond homegrown giants like Roche and Novartis. The new findings, outlined by the Swiss Biotech Association in its latest annual report […]

May 2, 2022

In the midst of new emerging therapy projects under development, the progress of innovative manufacturing technologies is also growing. One of the newest emerging platforms for biologics manufacturing is the plant made pharmaceutical platform (PMP). PMP has come on-stage recently […]

April 25, 2022

The results didn’t add up. BridgeBio Pharma, a young biotech trying to bring its first big drug to market, followed the blueprint of one of the world’s largest pharmaceutical companies. It made a medicine meant to work like the one […]

March 22, 2022

High performance liquid chromatography (HPLC) and biomanufacturing have a long, interwoven history. HPLC supports every aspect of biotherapeutic discovery, development, and manufacturing, to the point where thinking of biotech absent HPLC becomes difficult. Through their ongoing co-evolution HPLC will assume […]

March 16, 2022

Top execs at Taiwanese biosimilars outfit JHL Biotech are headed to prison after pleading guilty last August to stealing trade secrets from Roche’s Genentech. Racho Jordanov, co-founder and former CEO at JHL, and Rose Lin, another co-founder and the company’s […]

February 14, 2022

The stock market rout that has engulfed the biotech industry is beginning to work its way down to privately held startups and the venture investors who back them. Already, the pace of biotech initial public offerings, which accelerated in recent […]

February 8, 2022

Margit Holzer, PhD, owner of Ulysse Consult, is chairing a session on the future of bioprocessing at this year’s Bioprocessing Summit Europe. She talks to GEN about new molecules, technologies, and products. Holzer: We need to think about the new […]

February 2, 2022

Work on RNA-based drugs and vaccines had been progressing quietly for some two decades. Then, when COVID-19 struck, it became an overnight sensation, attracting the interest of public and private entities eager to fight the pandemic. RNA-based drugs and vaccines […]

January 26, 2022

From the Pfizer/BioNTech and Oxford/AstraZeneca vaccines to GSK’s lifesaving antibody treatments, European innovation has played a crucial role in the global response to COVID-19. But while the pandemic triggered a boom in biotech initial public offerings, according to Hannah Kuchler, […]

January 18, 2022

Developing drugs is a capital-intensive activity, and never more so than when a biotech company wants to move from preclinical development to more expensive clinical trials. Early on, there are often angel investments and/or academic or government grants, but the […]

January 12, 2022

The momentum of biotech and biopharma companies is on the rise in anticipation of a new wave of emerging therapies moving through the industry’s development pipeline. In addition, the COVID-19 pandemic highlighted the importance of companies that can react quickly […]

January 7, 2022

Merck is taking a deep dive into complex proteins with the help of artificial-intelligence-powered drug discovery company Absci. The two companies have signed a research collaboration for up to three targets in a deal worth up to $610 million in […]

January 6, 2022

Eikon Therapeutics, the drug discovery startup with a former Merck & Co. research chief at the helm, has appointed a pantheon of biotech veterans on its quest to take its live-cell imaging platform to the next level. The biotech unveiled […]

December 28, 2021

Anton Middelberg, PhD, deputy vice-chancellor and vice-president of research at the University of Adelaide in Australia, believes industry reluctance to go continuous reflects the traditional focus on batch-mode production and, in some areas, the technical challenges. “The complexity in continuous […]

December 22, 2021

We thought we’d finally get to see what a post-pandemic world looked like in 2022, but thanks to omicron, it seems we’re in for another round. Biotech has been shaped by the pandemic in ways that may be permanent, just […]

December 7, 2021

Gary Glick, a chemist and well-known biotech entrepreneur, has raised more than $200 million to launch the latest company aiming to harness advances in medicinal chemistry to invent new drugs for cancer and inflammatory diseases. Called Odyssey Therapeutics, the startup […]

December 1, 2021

The momentum of biotech and biopharma companies is on the rise in anticipation of a new wave of emerging therapies moving through the industry’s development pipeline. In addition, the COVID-19 pandemic highlighted the importance of companies that can react quickly […]

November 24, 2021

Large biomanufacturing facilities, including some that may be involved in producing COVID-19 vaccines and drugs, are being targeted by a malware threat that seems to have an unprecedented level of sophistication, according to a cybersecurity group. The Bioeconomy Information Sharing […]